The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospective DPYD testing and dose adjustment in colorectal cancer patients prior to fluoropyrimidine-based chemotherapy: Experience in a regional cancer center.
 
Janet Shirley Graham
Consulting or Advisory Role - Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre
Speakers' Bureau - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Nucana; Nucana; Nucana; Nucana
 
Jocelyn Saunders
No Relationships to Disclose
 
Gregory Naylor
No Relationships to Disclose
 
Christine Crearie
No Relationships to Disclose
 
Wendy Campbell
No Relationships to Disclose
 
Tareq Abdullah
No Relationships to Disclose
 
Mary G. Dunn
No Relationships to Disclose
 
Nicholas James MacLeod
Honoraria - SERVIER; SERVIER; SERVIER; SERVIER
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer
 
Alec McDonald
No Relationships to Disclose
 
Gillian McGaffin
No Relationships to Disclose
 
Anne Jane McKillop
No Relationships to Disclose
 
Laura Miller
No Relationships to Disclose
 
Nazia Mohammed
No Relationships to Disclose
 
Aqilah Othman
No Relationships to Disclose
 
Liz Radford
No Relationships to Disclose
 
Karen Smith
No Relationships to Disclose
 
Dawn Jane Storey
No Relationships to Disclose
 
Nicola Williams
No Relationships to Disclose
 
Paul Westwood
No Relationships to Disclose
 
Richard H. Wilson
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; CV6 Therapeutics; CV6 Therapeutics; CV6 Therapeutics; CV6 Therapeutics; Halozyme; Halozyme; Halozyme; Halozyme; Karus Therapeutics; Karus Therapeutics; Karus Therapeutics; Karus Therapeutics; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche; Roche; Roche; Roche; Servier; Servier; Servier; Servier; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Research Funding - Almac Group (Inst); Almac Group (Inst); Almac Group (Inst); Almac Group (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Merck Serono; Merck Serono; Merck Serono; Merck Serono